Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
4984 studies found for:    "Leukemia"
Show Display Options
Rank Status Study
21 Completed Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Arsenic Trioxide;   Procedure: Autologous Transplantation;   Procedure: Allogenic Transplantation;   Drug: ATRA
22 Completed A Study in Participants With Acute Leukemia
Condition: Leukemia
Intervention: Drug: LY2090314
23 Completed Azacitidine in Treating Patients With Chronic Myelomonocytic Leukemia
Condition: Leukemia
Interventions: Drug: azacitidine;   Other: laboratory biomarker analysis
24 Completed Phase II Study of Perifosine in Patients With Refractory and Relapsed Leukemia
Condition: Leukemia
Intervention: Drug: perifosine
25 Unknown  JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia
Condition: Leukemia
Intervention: Drug: JVRS-100
26 Completed Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation
Condition: Leukemia
Interventions: Drug: CAMPATH-1H;   Drug: Anti-CD45;   Drug: Ara-C;   Drug: Cyclophosphamide;   Drug: Mesna;   Radiation: Total Body Irradiation
27 Completed Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
Condition: Leukemia
Interventions: Drug: Etoposide, Mitoxantrone, Clofarabine;   Drug: Clofarabine, Etoposide, Mitoxantrone
28 Active, not recruiting Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia
Condition: Leukemia
Interventions: Genetic: fluorescence in situ hybridization;   Genetic: mutation analysis;   Genetic: nucleic acid sequencing;   Genetic: polymerase chain reaction;   Genetic: western blotting;   Other: flow cytometry;   Other: laboratory biomarker analysis
29 Completed Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia
Condition: Leukemia
Intervention: Drug: CC-1088
30 Recruiting Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: Realgar-Indigo naturalis formula;   Drug: all-trans retinoic acid;   Drug: Arsenic trioxide;   Drug: Hydroxyurea
31 Completed BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia
Condition: Leukemia
Intervention: Drug: BL22
32 Unknown  Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Conditions: Relapsed Acute Promyelocytic Leukemia;   Refractory Acute Promyelocytic Leukemia
Interventions: Drug: Arsenic trioxide;   Drug: Trisenox
33 Completed Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia
Condition: Leukemia
Intervention: Biological: BL22 immunotoxin
34 Completed Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia
Condition: Leukemia
Intervention: Drug: gemcitabine hydrochloride
35 Recruiting Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia
Condition: Leukemia
Intervention: Biological: CD19-targeted CAR-T cells
36 Completed Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia
Condition: Leukemia
Interventions: Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunohistochemistry staining method
37 Active, not recruiting Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
Condition: Leukemia
Intervention: Drug: BAY1143572
38 Active, not recruiting
Has Results
Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia
Condition: Leukemia
Intervention: Drug: Dasatinib
39 Terminated Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia
Condition: Leukemia
Interventions: Drug: cyclophosphamide;   Drug: filgrastim;   Drug: recombinant interferon alfa;   Procedure: peripheral blood stem cell transplantation;   Procedure: radiation therapy
40 Withdrawn Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia
Condition: Leukemia
Intervention: Drug: arsenic trioxide

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.